<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01193608</url>
  </required_header>
  <id_info>
    <org_study_id>B2601001</org_study_id>
    <secondary_id>3245K1-1000</secondary_id>
    <nct_id>NCT01193608</nct_id>
  </id_info>
  <brief_title>Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease</brief_title>
  <official_title>A Phase 1, Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptive, Multiple Ascending Dose Study Of The Safety, Tolerability And Pharmacokinetics Of Aab-003 (Pf-05236812) In Subjects With Mild To Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the safety of multiple doses of AAB-003 (PF-05236812) in patients
      with mild to moderate Alzheimer's Disease. Patients will receive either AAB-003 (PF-05236812)
      or placebo. Each patient's participation will last approximately 41 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline up to 39 Weeks and at Early Withdrawal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Laboratory Abnormalities</measure>
    <time_frame>Baseline up to 39 Weeks and at Early Withdrawal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vital Signs of Potential Clinical Concern</measure>
    <time_frame>Baseline up to 39 Weeks and at Early Withdrawal</time_frame>
    <description>Criteria for potential clinical concern in vital signs included: supine/sitting pulse rate of less than (&lt;) 40 or more than (&gt;) 120 beats per minute (bpm), and standing pulse rate of &lt;40 or &gt;140 bpm; systolic blood pressure (SBP) of more than or equal to (&gt;=)30 millimeters of mercury (mm Hg) change from baseline in same posture and &lt;90 mm Hg; diastolic blood pressure (DBP) &gt;=20 mm Hg change from baseline in same posture and &lt;50 mm Hg. Only supine vital signs were planned for this study. Unplanned sitting vital signs were collected only in the 8/mg and placebo groups and also reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Physical Examination Findings</measure>
    <time_frame>Baseline up to 39 Weeks and at Early Withdrawal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Neurological Examination Findings</measure>
    <time_frame>Screening, Day 1 (Baseline) and Weeks 1,6,13,19,26,32, and 39, and at Early Withdrawal</time_frame>
    <description>The neurological examination was done to the extent needed to assess the participant for any potential changes in neurological status, as determined by the investigator. The minimum items assessed were level of consciousness, speech, cranial nerves, motor, sensory, coordination, gait, and tendon reflexes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) for AAB-003 at Day 1</measure>
    <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4 and 6 hours post start of infusion.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) for AAB-003 at at Week 26</measure>
    <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4, 6, and 24 hours post start of infusion.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Concentration (Cavg) for AAB-003 in Serum at Day 1</measure>
    <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4 and 6 hours post start of infusion.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Concentration (Cavg) for AAB-003 in Serum at Week 26</measure>
    <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4, 6, and 24 hours post start of infusion.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Serum Concentration (Tmax) for AAB-003 at Day 1</measure>
    <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4 and 6 hours post start of infusion.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Serum Concentration (Tmax) for AAB-003 at Week 26</measure>
    <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4, 6, and 24 hours post start of infusion.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for AAB-003 in Serum at Day 1</measure>
    <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4 and 6 hours post start of infusion.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for AAB-003 in Serum at Day 1</measure>
    <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4 and 6 hours post start of infusion.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for AAB-003 in Serum at Day 1</measure>
    <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4 and 6 hours post start of infusion.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for AAB-003 in Serum at Week 26</measure>
    <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4, 6, and 24 hours post start of infusion.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic Clearance (CL) for AAB-003 in Serum at Day 1</measure>
    <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4 and 6 hours post start of infusion.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic Clearance (CL) for AAB-003 in Serum at Week 26</measure>
    <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4, 6, and 24 hours post start of infusion.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) for AAB-003 in Serum at Day 1</measure>
    <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4 and 6 hours post start of infusion.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) for AAB-003 in Serum at Week 26</measure>
    <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4, 6, and 24 hours post start of infusion.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Decay Half-Life (t1/2) for AAB-003 at Day 1</measure>
    <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4 and 6 hours post start of infusion.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Decay Half-Life (t1/2) for AAB-003 at Week 26</measure>
    <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4, 6, and 24 hours post start of infusion.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Baseline up to Week 39 or Early Withdrawal</time_frame>
    <description>The C-SSRS assessed whether the participant experienced the following: completed suicide (1), suicide attempt (2) (response of &quot;Yes&quot; on &quot;actual attempt&quot;), preparatory acts toward imminent suicidal behavior (3)(&quot;Yes&quot; on &quot;preparatory acts or behavior&quot;), suicidal ideation (4) (&quot;Yes&quot; on &quot;wish to be dead&quot;, &quot;non-specific active suicidal thoughts&quot;, &quot;active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7)(&quot;Yes&quot; on &quot;Has participant engaged in non-suicidal self-injurious behavior&quot;).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With New Occurrence of Brain Magnetic Resonance Imaging (MRI) Finding</measure>
    <time_frame>Baseline up to Week 32.</time_frame>
    <description>Brain MRIs were collected during the course of study to assess for any potential drug-related changes that might have constituted a safety concern for study participants. Findings suggestive of either vasogenic edema (VE) or intracranial hemorrhage represented adverse events of special circumstance and were to be reported immediately.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vasogenic Edema of All Severity After Each Infusion Visit</measure>
    <time_frame>Day 1, Week 13, and Week 26</time_frame>
    <description>VE of the brain, identified via MRI, was identified as an adverse event of special circumstance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Change From Baseline and Absolute Values in Electrocardiogram (ECG) Meeting Categorical Summarization Criteria</measure>
    <time_frame>Baseline, Weeks 1,13,16,26,39 or Early Withdrawal</time_frame>
    <description>Criteria for ECG values of potential clinical concern are: interval between the start of the ECG P wave and the start of the QRS complex corresponding to the time between onset of atrial depolarization and onset of ventricular depolarization (PR): &gt;= 300 milliseconds (msec), and &gt;=25% increase when baseline &gt;=200 msec/ &gt;=50% increase when baseline less than or equal to (&lt;=) 200 msec; time from ECG Q wave to the end of S wave corresponding to ventricular depolarization (QRS): &gt;=200 msec, and &gt;=25% increase when baseline &gt;100 msec/ &gt;=50% increase when baseline &lt;=100 msec; QTc using Fridericia's formula (QTcF) interval: 450 to &lt;480 msec, &gt;=480 msec; QTcF change from baseline: 30 to &lt;60 msec, and &gt;=60 msec.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Participants With Positive Anti-product Antibody Response to AAB-003 in Serum</measure>
    <time_frame>Day 1 (predose), Week 13 (predose), Week 26 (predose) and Week 39 or Early Withdrawal</time_frame>
    <description>Human serum anti-drug antibodies (ADA) samples were analyzed for the presence or absence of anti-AAB-003 antibodies by enzyme-linked immunosorbent assay (ELISA) method</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) Score at Weeks 13, 26 and 39</measure>
    <time_frame>Baseline, Weeks 13, 26 and 39</time_frame>
    <description>The ADAS-cog 70 Point is a structured scale (approximately 40 min to complete) that evaluates memory, orientation, attention, reasoning, language and constructional praxis. This study used the 11-item cognitive subscale of the ADAS-Cog with scores ranging from 0 to 70 points; higher scores indicated greater cognitive impairment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Disability Assessment in Dementia (DAD) Score at Weeks 13, 26 and 39</measure>
    <time_frame>Baseline, Weeks 13, 26 and 39</time_frame>
    <description>The DAD is a functional assessment based on an interview with the caregiver that takes approximately 20 min to administer and it is comprised of 40 items, 17 related to self-care and 23 items involving instrumental activities of daily living. The DAD is scored from 0 to 100 (higher scores indicate better functioning).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Behavioral Symtoms as Measured by the Neuropsychiatric Inventory (NPI) at Weeks 13, 26 and 39</measure>
    <time_frame>Baseline, Weeks 13, 26 and 39</time_frame>
    <description>The NPI is an instrument used to assess changes of behavior that have appeared in a defined period of time in participants with Alzheimer's disease (AD) and other dementias. Twelve (12) behavioral areas are assessed in the NPI - delusions, apathy, hallucinations, disinhibition, agitation, irritability, depression, aberrant motor behavior, anxiety, nighttime behaviors, euphoria, appetite, and eating changes. The NPI score is based on frequency and severity of specific behaviors within these categories as reported by the caregiver. A separate caregiver distress score may also be included. The NPI ranges from 0 to 144 (higher scores indicate greater psychopathology).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline on the Clinical Dementia Rating (CDR) Sum of Boxes (CDR-SB) and Global CDR Rating at Weeks 26 and 39</measure>
    <time_frame>Baseline, Weeks 26 and 39</time_frame>
    <description>The CDR scale is a clinician-rated dementia staging instrument that tracks the progression of cognitive impairment in the following 6 categories - memory, orientation, judgment and problem solving, involvement in community affairs, home and hobbies, and personal care based on the CDR interview. The CDR is based on discussions between the clinician with the participant and caregiver using a structured format. A global CDR score is established by clinical scoring rules with values of 0 (no dementia), 0.5 (questionable dementia), 1 (mild dementia), 2 (moderate dementia), and 3 (severe dementia). A more quantitative version of the CDR scale is obtained by summing up the ratings in each of the 6 categories to provide the (CDR-SB). The CDR-SB scale ranges from 0 to 18 where higher score indicates severe dementia.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline on the Mini Mental State Exam (MMSE) Score at Weeks 13, 26, and 39</measure>
    <time_frame>Baseline, Weeks 13, 26 and 39</time_frame>
    <description>The MMSE is a brief 30-point questionnaire test that is used to assess cognition. It is commonly used to screen for dementia. In the time span of about 10 min, it samples various functions, including arithmetic, memory and orientation. Scores range from 0 to 30 (higher scores indicate less impairment) and participants with scores of 16 to 26 were eligible.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cerebrospinal Fluid (CSF) Concentration of AAB-003 at Week 32</measure>
    <time_frame>Week 32 or Early Withdrawal</time_frame>
    <description>Participants enrolled in the 2, 4 and 8 mg/kg cohorts participated in an optional CSF collection. Participants enrolled in the maximum tolerated dose (MTD) cohort were mandatorily collected for CSF.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in CSF Amyloid-beta x-40 Concentration at Week 32 for AAB-003 8 mg/kg and Placebo Groups</measure>
    <time_frame>Baseline and Week 32</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>CSF Amyloid-beta x-40 Concentration at Baseline and Week 32 for AAB-003 2 mg/kg and 4 mg/kg Groups</measure>
    <time_frame>Baseline and Week 32</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in CSF Amyloid-beta x-42 Concentration at Week 32 for AAB-003 8 mg/kg and Placebo Groups</measure>
    <time_frame>Baseline and Week 32</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>CSF Amyloid-beta x-42 Concentration at Baseline and Week 32 for AAB-003 2 mg/kg and 4 mg/kg Groups</measure>
    <time_frame>Baseline and Week 32</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in CSF Tau Concentration at Week 32 for AAB-003 8 mg/kg and Placebo Groups</measure>
    <time_frame>Baseline and Week 32</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>CSF Tau Concentration at Baseline and Week 32 for AAB-003 2 mg/kg and 4 mg/kg Groups</measure>
    <time_frame>Baseline and Week 32</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in CSF P-tau Concentration at Week 32 for AAB-003 8 mg/kg and Placebo Groups</measure>
    <time_frame>Baseline and Week 32</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>CSF P-tau Concentration at Baseline and Week 32 for AAB-003 2 mg/kg and 4 mg/kg Groups</measure>
    <time_frame>Baseline and Week 32</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for Amyloid-Beta x-40</measure>
    <time_frame>Weeks 1, 3, 6, 10, 13 (pre-dose, 1 hour [end of infusion]), Week 26 (pre-dose, 1 hour [end of infusion], 1.5, 2, 4, 6, and 24 hours post start of infusion), and Weeks 32 and 39.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) for Amyloid-Beta x-40</measure>
    <time_frame>Weeks 1, 3, 6, 10, 13 (pre-dose, 1 hour [end of infusion]), Week 26 (pre-dose, 1 hour [end of infusion], 1.5, 2, 4, 6, and 24 hours post start of infusion), and Weeks 32 and 39.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Amyloid-Beta x-40</measure>
    <time_frame>Baseline; Day 2 (24 hours post start of infusion); Weeks 1, 6, and 13 (pre-dose, 1 hour [end of infusion]), Week 26 (pre-dose, 1 hour [end of infusion], 1.5, 2, 4, 6, and 24 hours post start of infusion), and Weeks 32 and 39.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for Amyloid-Beta x-40</measure>
    <time_frame>Baseline; Day 2 (24 hours post start of infusion); Weeks 1, 6, and 13 (pre-dose, 1 hour [end of infusion]), Week 26 (pre-dose, 1 hour [end of infusion], 1.5, 2, 4, 6, and 24 hours post start of infusion), and Weeks 32 and 39.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for Amyloid-Beta x-40</measure>
    <time_frame>Weeks 1, 3, 6, 10, 13 (pre-dose, 1 hour [end of infusion]), Week 26 (pre-dose, 1 hour [end of infusion], 1.5, 2, 4, 6, and 24 hours post start of infusion), and Weeks 32 and 39.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Decay Half-Life (t1/2) for Amyloid-Beta x-40</measure>
    <time_frame>Baseline; Day 2 (24 hours post start of infusion); Weeks 1, 6, and 13 (pre-dose, 1 hour [end of infusion]), Week 26 (pre-dose, 1 hour [end of infusion], 1.5, 2, 4, 6, and 24 hours post start of infusion), and Weeks 32 and 39.</time_frame>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>0.5 mg/kg AAB-003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg/kg AAB-003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2 mg/kg AAB-003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4 mg/kg AAB-003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>8 mg/kg AAB-003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AAB-003 (PF-05236812)</intervention_name>
    <description>0.5 mg/kg AAB-003, IV</description>
    <arm_group_label>0.5 mg/kg AAB-003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AAB-003 (PF-05236812)</intervention_name>
    <description>1 mg/kg AAB-003, IV</description>
    <arm_group_label>1 mg/kg AAB-003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AAB-003 (PF-05236812)</intervention_name>
    <description>2 mg/kg AAB-003, IV</description>
    <arm_group_label>2 mg/kg AAB-003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AAB-003 (PF-05236812)</intervention_name>
    <description>4 mg/kg AAB-003, IV</description>
    <arm_group_label>4 mg/kg AAB-003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AAB-003 (PF-05236812)</intervention_name>
    <description>8 mg/kg AAB-003, IV</description>
    <arm_group_label>8 mg/kg AAB-003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, IV</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of probable Alzheimer's Disease with MMSE score of 16-26, and brain MRI
             consistent with the diagnosis of Alzheimer's Disease

          -  Concurrent use of cholinesterase inhibitor or memantine allowed, if stable.

          -  Caregiver will participate and be able to attend clinic visits with patient

        Exclusion Criteria:

          -  Significant neurological disease other than Alzheimer's Disease

          -  Major psychiatric disorder

          -  Contraindication to undergo brain MRI (e.g., pacemaker, CSF shunt, or foreign metal
             objects in the body)

          -  Women of childbearing potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Early Phase Investigational Center</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Clinical Research Center of Escondido</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Clinical</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franck's Pharmacy</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Munroe Regional Medical Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Imaging of Ocala</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34481</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foers Medical Arts Pharmacy</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CBH Health, LLC</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borgess Medical Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borgess Research Institute</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KNI/Southwest Michigan Imaging Center, LLC</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brentwood Behavioral Healthcare</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marty's Pharmacy</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precise Research Centers</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millennium Psychiatric Associates, LLC</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DePaul Health Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memory Enhancement Center of America, Inc.</name>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <zip>07724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacare USA</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08837</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Jersey Radiology</name>
      <address>
        <city>Oakhurst</city>
        <state>New Jersey</state>
        <zip>07755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belmont Center for Comprehensive Treatment</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19131-1689</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital, Department of Neurology</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital, Department of Neurology</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center, Department of Neurology</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASAN Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center, Department of Neurology</name>
      <address>
        <city>Seoul</city>
        <zip>143-914</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2601001&amp;StudyName=Study%20Evaluating%20The%20Safety%20Of%20AAB-003%20%28PF-05236812%29%20In%20Subjects%20With%20Alzheimer%27s%20Disease%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2010</study_first_submitted>
  <study_first_submitted_qc>August 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2010</study_first_posted>
  <results_first_submitted>June 15, 2016</results_first_submitted>
  <results_first_submitted_qc>January 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2017</results_first_posted>
  <last_update_submitted>January 3, 2017</last_update_submitted>
  <last_update_submitted_qc>January 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Randomized</keyword>
  <keyword>Safety Study</keyword>
  <keyword>Adaptive</keyword>
  <keyword>Double Blind</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AAB-003 0.5 mg/kg</title>
          <description>Participants received AAB-003 0.5 milligram/kilogram (mg/kg) 1-hour intravenous (IV) infusion (infusion of AAB-003 and 20 milliliter (mL) normal saline flush of IV line) once every 13 weeks on Day 1, Week 13 and Week 26 for a total of 3 infusions over the course of study. A final follow-up visit was performed at Week 39, 13 weeks after the last infusion.</description>
        </group>
        <group group_id="P2">
          <title>AAB-003 1 mg/kg</title>
          <description>Participants received AAB-003 1 mg/kg 1-hour IV infusion (infusion of AAB-003 and 20 mL normal saline flush of IV line) once every 13 weeks on Day 1, Week 13 and Week 26 for a total of 3 infusions over the course of study. A final follow-up visit was performed at Week 39, 13 weeks after the last infusion.</description>
        </group>
        <group group_id="P3">
          <title>AAB-003 2 mg/kg</title>
          <description>Participants received AAB-003 2 mg/kg 1-hour IV infusion (infusion of AAB-003 and 20 mL normal saline flush of IV line) once every 13 weeks on Day 1, Week 13 and Week 26 for a total of 3 infusions over the course of study. A final follow-up visit was performed at Week 39, 13 weeks after the last infusion.</description>
        </group>
        <group group_id="P4">
          <title>AAB-003 4 mg/kg</title>
          <description>Participants received AAB-003 4 mg/kg 1-hour IV infusion (infusion of AAB-003 and 20 mL normal saline flush of IV line) once every 13 weeks on Day 1, Week 13 and Week 26 for a total of 3 infusions over the course of study. A final follow-up visit was performed at Week 39, 13 weeks after the last infusion.</description>
        </group>
        <group group_id="P5">
          <title>AAB-003 8 mg/kg</title>
          <description>Participants received AAB-003 8 mg/kg 1-hour IV infusion (infusion of AAB-003 and 20 mL normal saline flush of IV line) once every 13 weeks on Day 1, Week 13 and Week 26 for a total of 3 infusions over the course of study. A final follow-up visit was performed at Week 39, 13 weeks after the last infusion.</description>
        </group>
        <group group_id="P6">
          <title>Placebo</title>
          <description>Participants received placebo matched to AAB-003 1-hour IV infusion (infusion of placebo matched to AAB-003 and 20 mL normal saline flush of IV line) once every 13 weeks on Day 1, Week 13 and Week 26 for a total of 3 infusions over the course of study. A final follow-up visit was performed at Week 39, 13 weeks after the last infusion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="24"/>
                <participants group_id="P6" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>AAB-003 0.5 mg/kg</title>
          <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
        </group>
        <group group_id="B2">
          <title>AAB-003 1 mg/kg</title>
          <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
        </group>
        <group group_id="B3">
          <title>AAB-003 2 mg/kg</title>
          <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
        </group>
        <group group_id="B4">
          <title>AAB-003 4 mg/kg</title>
          <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
        </group>
        <group group_id="B5">
          <title>AAB-003 8 mg/kg</title>
          <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
        </group>
        <group group_id="B6">
          <title>Placebo</title>
          <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="17"/>
            <count group_id="B5" value="24"/>
            <count group_id="B6" value="19"/>
            <count group_id="B7" value="88"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.5" spread="6.4"/>
                    <measurement group_id="B2" value="67.2" spread="7.4"/>
                    <measurement group_id="B3" value="70.7" spread="10.8"/>
                    <measurement group_id="B4" value="71.5" spread="8.8"/>
                    <measurement group_id="B5" value="64.5" spread="7.6"/>
                    <measurement group_id="B6" value="71.1" spread="7.6"/>
                    <measurement group_id="B7" value="68.6" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
        <time_frame>Baseline up to 39 Weeks and at Early Withdrawal</time_frame>
        <population>Safety analysis set consisted of all participants who received at least one infusion of study medication (including partial infusions). A TEAE was defined as an untoward medical occurrence reported by the participant or investigator following administration of at least one dose of AAB-003.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
          <population>Safety analysis set consisted of all participants who received at least one infusion of study medication (including partial infusions). A TEAE was defined as an untoward medical occurrence reported by the participant or investigator following administration of at least one dose of AAB-003.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with Adverse Events (AEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Serious Adverse Events (SAEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants Discontinued due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Laboratory Abnormalities</title>
        <time_frame>Baseline up to 39 Weeks and at Early Withdrawal</time_frame>
        <population>Safety analysis set consisted of all participants who received at least one infusion of study medication (including partial infusions). Laboratory test parameters included hematology, coagulation, liver function, renal function, electrolytes, clinical chemistry, and urinalysis (dipstick and microscopy).</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Abnormalities</title>
          <population>Safety analysis set consisted of all participants who received at least one infusion of study medication (including partial infusions). Laboratory test parameters included hematology, coagulation, liver function, renal function, electrolytes, clinical chemistry, and urinalysis (dipstick and microscopy).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vital Signs of Potential Clinical Concern</title>
        <description>Criteria for potential clinical concern in vital signs included: supine/sitting pulse rate of less than (&lt;) 40 or more than (&gt;) 120 beats per minute (bpm), and standing pulse rate of &lt;40 or &gt;140 bpm; systolic blood pressure (SBP) of more than or equal to (&gt;=)30 millimeters of mercury (mm Hg) change from baseline in same posture and &lt;90 mm Hg; diastolic blood pressure (DBP) &gt;=20 mm Hg change from baseline in same posture and &lt;50 mm Hg. Only supine vital signs were planned for this study. Unplanned sitting vital signs were collected only in the 8/mg and placebo groups and also reported.</description>
        <time_frame>Baseline up to 39 Weeks and at Early Withdrawal</time_frame>
        <population>Safety analysis set consisted of all participants who received at least one infusion of study medication (including partial infusions).</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Signs of Potential Clinical Concern</title>
          <description>Criteria for potential clinical concern in vital signs included: supine/sitting pulse rate of less than (&lt;) 40 or more than (&gt;) 120 beats per minute (bpm), and standing pulse rate of &lt;40 or &gt;140 bpm; systolic blood pressure (SBP) of more than or equal to (&gt;=)30 millimeters of mercury (mm Hg) change from baseline in same posture and &lt;90 mm Hg; diastolic blood pressure (DBP) &gt;=20 mm Hg change from baseline in same posture and &lt;50 mm Hg. Only supine vital signs were planned for this study. Unplanned sitting vital signs were collected only in the 8/mg and placebo groups and also reported.</description>
          <population>Safety analysis set consisted of all participants who received at least one infusion of study medication (including partial infusions).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Supine SBP &lt;90 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum increase in supine SBP &gt;=30 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum decrease in supine SBP &gt;=30 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting SBP &lt;90 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine DBP &lt;50 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum increase in supine DBP &gt;=20 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum decrease in supine DBP &gt;=20 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting DBP &lt;50 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine pulse rate &lt;40 or &gt;120 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting pulse rate &lt;40 or &gt;120 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Physical Examination Findings</title>
        <time_frame>Baseline up to 39 Weeks and at Early Withdrawal</time_frame>
        <population>Safety analysis set consisted of all participants who received at least one infusion of study medication (including partial infusions). A full physical examination consisted of abdomen, genitourinary, cardiovascular systems, lungs, lymph nodes, mouth, musculoskeletal, general, skin, extremities, head, ears, eyes, nose, throat and thyroid.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Physical Examination Findings</title>
          <population>Safety analysis set consisted of all participants who received at least one infusion of study medication (including partial infusions). A full physical examination consisted of abdomen, genitourinary, cardiovascular systems, lungs, lymph nodes, mouth, musculoskeletal, general, skin, extremities, head, ears, eyes, nose, throat and thyroid.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Neurological Examination Findings</title>
        <description>The neurological examination was done to the extent needed to assess the participant for any potential changes in neurological status, as determined by the investigator. The minimum items assessed were level of consciousness, speech, cranial nerves, motor, sensory, coordination, gait, and tendon reflexes.</description>
        <time_frame>Screening, Day 1 (Baseline) and Weeks 1,6,13,19,26,32, and 39, and at Early Withdrawal</time_frame>
        <population>Safety analysis set consisted of all participants who received at least one infusion of study medication (including partial infusions). n = number of evaluable participants at the corresponding time point.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Neurological Examination Findings</title>
          <description>The neurological examination was done to the extent needed to assess the participant for any potential changes in neurological status, as determined by the investigator. The minimum items assessed were level of consciousness, speech, cranial nerves, motor, sensory, coordination, gait, and tendon reflexes.</description>
          <population>Safety analysis set consisted of all participants who received at least one infusion of study medication (including partial infusions). n = number of evaluable participants at the corresponding time point.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=6,6,16,17,24,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=6,6,16,17,24,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=6,6,16,17,24,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=6,6,15,16,22,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 19 (n=6,5,14,15,21,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=6,5,14,14,18,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=6,5,14,14,19,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 39 (n=6,4,14,14,19,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Serum Concentration (Cmax) for AAB-003 at Day 1</title>
        <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4 and 6 hours post start of infusion.</time_frame>
        <population>Pharmacokinetic (PK) Analysis Set consisted of all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentration (Cmax) for AAB-003 at Day 1</title>
          <population>Pharmacokinetic (PK) Analysis Set consisted of all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment.</population>
          <units>microgram per milliliter (mcg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.79" spread="48"/>
                    <measurement group_id="O2" value="32.05" spread="33"/>
                    <measurement group_id="O3" value="58.74" spread="21"/>
                    <measurement group_id="O4" value="122.4" spread="14"/>
                    <measurement group_id="O5" value="223.7" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Serum Concentration (Cmax) for AAB-003 at at Week 26</title>
        <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4, 6, and 24 hours post start of infusion.</time_frame>
        <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentration (Cmax) for AAB-003 at at Week 26</title>
          <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.53" spread="33"/>
                    <measurement group_id="O2" value="38.51" spread="25"/>
                    <measurement group_id="O3" value="60.17" spread="38"/>
                    <measurement group_id="O4" value="108.5" spread="41"/>
                    <measurement group_id="O5" value="228.9" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Concentration (Cavg) for AAB-003 in Serum at Day 1</title>
        <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4 and 6 hours post start of infusion.</time_frame>
        <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Average Concentration (Cavg) for AAB-003 in Serum at Day 1</title>
          <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.465" spread="30"/>
                    <measurement group_id="O2" value="6.545" spread="33"/>
                    <measurement group_id="O3" value="10.83" spread="16"/>
                    <measurement group_id="O4" value="20.37" spread="20"/>
                    <measurement group_id="O5" value="36.78" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Concentration (Cavg) for AAB-003 in Serum at Week 26</title>
        <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4, 6, and 24 hours post start of infusion.</time_frame>
        <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Average Concentration (Cavg) for AAB-003 in Serum at Week 26</title>
          <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.435" spread="22"/>
                    <measurement group_id="O2" value="7.171" spread="9"/>
                    <measurement group_id="O3" value="12.56" spread="28"/>
                    <measurement group_id="O4" value="22.52" spread="29"/>
                    <measurement group_id="O5" value="46.12" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Serum Concentration (Tmax) for AAB-003 at Day 1</title>
        <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4 and 6 hours post start of infusion.</time_frame>
        <population>PK Analysis Set consisted of all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Serum Concentration (Tmax) for AAB-003 at Day 1</title>
          <population>PK Analysis Set consisted of all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment.</population>
          <units>Hours (hr)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="30" lower_limit="1.50" upper_limit="6.05"/>
                    <measurement group_id="O2" value="4.00" spread="33" lower_limit="2.17" upper_limit="6.02"/>
                    <measurement group_id="O3" value="1.54" spread="16" lower_limit="1.20" upper_limit="2.12"/>
                    <measurement group_id="O4" value="1.50" spread="20" lower_limit="1.00" upper_limit="24.0"/>
                    <measurement group_id="O5" value="3.02" spread="24" lower_limit="1.07" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Serum Concentration (Tmax) for AAB-003 at Week 26</title>
        <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4, 6, and 24 hours post start of infusion.</time_frame>
        <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Serum Concentration (Tmax) for AAB-003 at Week 26</title>
          <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
          <units>Hours (hr)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="22" lower_limit="1.30" upper_limit="4.05"/>
                    <measurement group_id="O2" value="2.00" spread="9" lower_limit="1.25" upper_limit="5.95"/>
                    <measurement group_id="O3" value="1.64" spread="28" lower_limit="1.05" upper_limit="6.03"/>
                    <measurement group_id="O4" value="2.00" spread="29" lower_limit="1.03" upper_limit="6.03"/>
                    <measurement group_id="O5" value="1.50" spread="34" lower_limit="1.07" upper_limit="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for AAB-003 in Serum at Day 1</title>
        <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4 and 6 hours post start of infusion.</time_frame>
        <population>PK Analysis Set consisted of all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for AAB-003 in Serum at Day 1</title>
          <population>PK Analysis Set consisted of all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment</population>
          <units>mcg*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5397" spread="30"/>
                    <measurement group_id="O2" value="13470" spread="33"/>
                    <measurement group_id="O3" value="22960" spread="19"/>
                    <measurement group_id="O4" value="44000" spread="20"/>
                    <measurement group_id="O5" value="79130" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for AAB-003 in Serum at Day 1</title>
        <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4 and 6 hours post start of infusion.</time_frame>
        <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for AAB-003 in Serum at Day 1</title>
          <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
          <units>mcg*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5597" spread="39"/>
                    <measurement group_id="O2" value="13060" spread="18"/>
                    <measurement group_id="O3" value="25270" spread="17"/>
                    <measurement group_id="O4" value="46430" spread="21"/>
                    <measurement group_id="O5" value="82140" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for AAB-003 in Serum at Day 1</title>
        <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4 and 6 hours post start of infusion.</time_frame>
        <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for AAB-003 in Serum at Day 1</title>
          <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
          <units>mcg*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5384" spread="30" lower_limit="1.50" upper_limit="6.05"/>
                    <measurement group_id="O2" value="14300" spread="33" lower_limit="2.17" upper_limit="6.02"/>
                    <measurement group_id="O3" value="23660" spread="16" lower_limit="1.20" upper_limit="2.12"/>
                    <measurement group_id="O4" value="44490" spread="20" lower_limit="1.00" upper_limit="24.0"/>
                    <measurement group_id="O5" value="80320" spread="24" lower_limit="1.07" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for AAB-003 in Serum at Week 26</title>
        <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4, 6, and 24 hours post start of infusion.</time_frame>
        <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for AAB-003 in Serum at Week 26</title>
          <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
          <units>mcg*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7502" spread="22" lower_limit="1.30" upper_limit="4.05"/>
                    <measurement group_id="O2" value="15660" spread="9" lower_limit="1.25" upper_limit="5.95"/>
                    <measurement group_id="O3" value="27440" spread="28" lower_limit="1.05" upper_limit="6.03"/>
                    <measurement group_id="O4" value="49180" spread="29" lower_limit="1.03" upper_limit="6.03"/>
                    <measurement group_id="O5" value="100700" spread="34" lower_limit="1.07" upper_limit="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Systemic Clearance (CL) for AAB-003 in Serum at Day 1</title>
        <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4 and 6 hours post start of infusion.</time_frame>
        <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Clearance (CL) for AAB-003 in Serum at Day 1</title>
          <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
          <units>milliliter/hour/kilogram (mL/hr/kg)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08934" spread="39"/>
                    <measurement group_id="O2" value="0.07657" spread="18"/>
                    <measurement group_id="O3" value="0.07914" spread="17"/>
                    <measurement group_id="O4" value="0.08615" spread="21"/>
                    <measurement group_id="O5" value="0.09739" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Systemic Clearance (CL) for AAB-003 in Serum at Week 26</title>
        <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4, 6, and 24 hours post start of infusion.</time_frame>
        <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Clearance (CL) for AAB-003 in Serum at Week 26</title>
          <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
          <units>mL/hr/kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06665" spread="22"/>
                    <measurement group_id="O2" value="0.06385" spread="9"/>
                    <measurement group_id="O3" value="0.07289" spread="28"/>
                    <measurement group_id="O4" value="0.08133" spread="29"/>
                    <measurement group_id="O5" value="0.07943" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Volume of Distribution at Steady State (Vss) for AAB-003 in Serum at Day 1</title>
        <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4 and 6 hours post start of infusion.</time_frame>
        <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State (Vss) for AAB-003 in Serum at Day 1</title>
          <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
          <units>mL/kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.44" spread="38"/>
                    <measurement group_id="O2" value="59.74" spread="37"/>
                    <measurement group_id="O3" value="61.67" spread="21"/>
                    <measurement group_id="O4" value="60.44" spread="26"/>
                    <measurement group_id="O5" value="75.12" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Volume of Distribution at Steady State (Vss) for AAB-003 in Serum at Week 26</title>
        <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4, 6, and 24 hours post start of infusion.</time_frame>
        <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State (Vss) for AAB-003 in Serum at Week 26</title>
          <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
          <units>mL/kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.66" spread="18"/>
                    <measurement group_id="O2" value="48.27" spread="9"/>
                    <measurement group_id="O3" value="56.90" spread="37"/>
                    <measurement group_id="O4" value="65.11" spread="23"/>
                    <measurement group_id="O5" value="61.24" spread="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Decay Half-Life (t1/2) for AAB-003 at Day 1</title>
        <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4 and 6 hours post start of infusion.</time_frame>
        <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Decay Half-Life (t1/2) for AAB-003 at Day 1</title>
          <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.77" spread="6.9880"/>
                    <measurement group_id="O2" value="20.04" spread="8.9210"/>
                    <measurement group_id="O3" value="24.45" spread="4.8686"/>
                    <measurement group_id="O4" value="21.10" spread="5.2000"/>
                    <measurement group_id="O5" value="22.89" spread="4.5086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Decay Half-Life (t1/2) for AAB-003 at Week 26</title>
        <time_frame>Pre-dose, 1 hour (end of infusion), 1.5, 2, 4, 6, and 24 hours post start of infusion.</time_frame>
        <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Decay Half-Life (t1/2) for AAB-003 at Week 26</title>
          <population>Evaluable participants in the PK analysis set (all randomized participants who received at least one infusion of study medication and have at least one post-dose PK parameter assessment).</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.41" spread="6.8638"/>
                    <measurement group_id="O2" value="22.32" spread="3.1454"/>
                    <measurement group_id="O3" value="22.83" spread="4.1356"/>
                    <measurement group_id="O4" value="22.27" spread="3.2448"/>
                    <measurement group_id="O5" value="22.81" spread="4.3455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)</title>
        <description>The C-SSRS assessed whether the participant experienced the following: completed suicide (1), suicide attempt (2) (response of Yes on actual attempt), preparatory acts toward imminent suicidal behavior (3)(Yes on preparatory acts or behavior), suicidal ideation (4) (Yes on wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7)(Yes on Has participant engaged in non-suicidal self-injurious behavior).</description>
        <time_frame>Baseline up to Week 39 or Early Withdrawal</time_frame>
        <population>Safety Analysis Set included all participants who received at least one infusion of study medication (including partial infusions).</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)</title>
          <description>The C-SSRS assessed whether the participant experienced the following: completed suicide (1), suicide attempt (2) (response of Yes on actual attempt), preparatory acts toward imminent suicidal behavior (3)(Yes on preparatory acts or behavior), suicidal ideation (4) (Yes on wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7)(Yes on Has participant engaged in non-suicidal self-injurious behavior).</description>
          <population>Safety Analysis Set included all participants who received at least one infusion of study medication (including partial infusions).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With New Occurrence of Brain Magnetic Resonance Imaging (MRI) Finding</title>
        <description>Brain MRIs were collected during the course of study to assess for any potential drug-related changes that might have constituted a safety concern for study participants. Findings suggestive of either vasogenic edema (VE) or intracranial hemorrhage represented adverse events of special circumstance and were to be reported immediately.</description>
        <time_frame>Baseline up to Week 32.</time_frame>
        <population>Safety Analysis Set included all participants who received an infusion of study medication (including partial infusions).</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New Occurrence of Brain Magnetic Resonance Imaging (MRI) Finding</title>
          <description>Brain MRIs were collected during the course of study to assess for any potential drug-related changes that might have constituted a safety concern for study participants. Findings suggestive of either vasogenic edema (VE) or intracranial hemorrhage represented adverse events of special circumstance and were to be reported immediately.</description>
          <population>Safety Analysis Set included all participants who received an infusion of study medication (including partial infusions).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vasogenic Edema of All Severity After Each Infusion Visit</title>
        <description>VE of the brain, identified via MRI, was identified as an adverse event of special circumstance.</description>
        <time_frame>Day 1, Week 13, and Week 26</time_frame>
        <population>Safety Analysis Set included all participants who received an infusion of study medication, including partial infusions. n = number of evaluable participants at the corresponding timeframe.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vasogenic Edema of All Severity After Each Infusion Visit</title>
          <description>VE of the brain, identified via MRI, was identified as an adverse event of special circumstance.</description>
          <population>Safety Analysis Set included all participants who received an infusion of study medication, including partial infusions. n = number of evaluable participants at the corresponding timeframe.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=6,6,16,17,24,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=6,5,15,16,21,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=6,5,14,14,17,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Change From Baseline and Absolute Values in Electrocardiogram (ECG) Meeting Categorical Summarization Criteria</title>
        <description>Criteria for ECG values of potential clinical concern are: interval between the start of the ECG P wave and the start of the QRS complex corresponding to the time between onset of atrial depolarization and onset of ventricular depolarization (PR): &gt;= 300 milliseconds (msec), and &gt;=25% increase when baseline &gt;=200 msec/ &gt;=50% increase when baseline less than or equal to (&lt;=) 200 msec; time from ECG Q wave to the end of S wave corresponding to ventricular depolarization (QRS): &gt;=200 msec, and &gt;=25% increase when baseline &gt;100 msec/ &gt;=50% increase when baseline &lt;=100 msec; QTc using Fridericia's formula (QTcF) interval: 450 to &lt;480 msec, &gt;=480 msec; QTcF change from baseline: 30 to &lt;60 msec, and &gt;=60 msec.</description>
        <time_frame>Baseline, Weeks 1,13,16,26,39 or Early Withdrawal</time_frame>
        <population>Safety Analysis Set included all participants who received an infusion of study medication (including partial infusions).</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change From Baseline and Absolute Values in Electrocardiogram (ECG) Meeting Categorical Summarization Criteria</title>
          <description>Criteria for ECG values of potential clinical concern are: interval between the start of the ECG P wave and the start of the QRS complex corresponding to the time between onset of atrial depolarization and onset of ventricular depolarization (PR): &gt;= 300 milliseconds (msec), and &gt;=25% increase when baseline &gt;=200 msec/ &gt;=50% increase when baseline less than or equal to (&lt;=) 200 msec; time from ECG Q wave to the end of S wave corresponding to ventricular depolarization (QRS): &gt;=200 msec, and &gt;=25% increase when baseline &gt;100 msec/ &gt;=50% increase when baseline &lt;=100 msec; QTc using Fridericia's formula (QTcF) interval: 450 to &lt;480 msec, &gt;=480 msec; QTcF change from baseline: 30 to &lt;60 msec, and &gt;=60 msec.</description>
          <population>Safety Analysis Set included all participants who received an infusion of study medication (including partial infusions).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Maximum PR Interval &gt;=300 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum QRS Complex &gt;=200 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum QTcF Interval 450 to &lt;480 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum QTcF Interval 480 to &lt;500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum QTcF Interval &gt;=500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval &gt;=25/50% increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Complex &gt;=25/50% increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum QTcF Increase from Baseline 30 to &lt;60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum QTcF Interval Increase &gt;=60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Positive Anti-product Antibody Response to AAB-003 in Serum</title>
        <description>Human serum anti-drug antibodies (ADA) samples were analyzed for the presence or absence of anti-AAB-003 antibodies by enzyme-linked immunosorbent assay (ELISA) method</description>
        <time_frame>Day 1 (predose), Week 13 (predose), Week 26 (predose) and Week 39 or Early Withdrawal</time_frame>
        <population>All participants who received an infusion of study medication. n = number of evaluable participants at the corresponding timeframe.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Anti-product Antibody Response to AAB-003 in Serum</title>
          <description>Human serum anti-drug antibodies (ADA) samples were analyzed for the presence or absence of anti-AAB-003 antibodies by enzyme-linked immunosorbent assay (ELISA) method</description>
          <population>All participants who received an infusion of study medication. n = number of evaluable participants at the corresponding timeframe.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=6,6,16,17,24,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=6,5,15,16,22,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=6,5,14,14,17,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 39 (n=6,4,14,14,19,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) Score at Weeks 13, 26 and 39</title>
        <description>The ADAS-cog 70 Point is a structured scale (approximately 40 min to complete) that evaluates memory, orientation, attention, reasoning, language and constructional praxis. This study used the 11-item cognitive subscale of the ADAS-Cog with scores ranging from 0 to 70 points; higher scores indicated greater cognitive impairment.</description>
        <time_frame>Baseline, Weeks 13, 26 and 39</time_frame>
        <population>All participants who were randomized to a treatment and received at least one infusion of study medication. n = number of evaluable participants at the corresponding timeframe.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) Score at Weeks 13, 26 and 39</title>
          <description>The ADAS-cog 70 Point is a structured scale (approximately 40 min to complete) that evaluates memory, orientation, attention, reasoning, language and constructional praxis. This study used the 11-item cognitive subscale of the ADAS-Cog with scores ranging from 0 to 70 points; higher scores indicated greater cognitive impairment.</description>
          <population>All participants who were randomized to a treatment and received at least one infusion of study medication. n = number of evaluable participants at the corresponding timeframe.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=6,6,16,17,24,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="3.73"/>
                    <measurement group_id="O2" value="20.4" spread="7.49"/>
                    <measurement group_id="O3" value="21.6" spread="10.76"/>
                    <measurement group_id="O4" value="23.0" spread="11.15"/>
                    <measurement group_id="O5" value="18.0" spread="7.28"/>
                    <measurement group_id="O6" value="18.4" spread="7.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=6,5,15,15,22,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.45"/>
                    <measurement group_id="O2" value="3.3" spread="4.39"/>
                    <measurement group_id="O3" value="-0.4" spread="5.08"/>
                    <measurement group_id="O4" value="3.2" spread="4.18"/>
                    <measurement group_id="O5" value="-1.2" spread="4.20"/>
                    <measurement group_id="O6" value="0.2" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=6,5,14,13,18,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="2.73"/>
                    <measurement group_id="O2" value="0.7" spread="4.73"/>
                    <measurement group_id="O3" value="0.5" spread="5.40"/>
                    <measurement group_id="O4" value="3.3" spread="5.55"/>
                    <measurement group_id="O5" value="-0.8" spread="5.07"/>
                    <measurement group_id="O6" value="1.4" spread="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 39 (n=6,4,14,13,19,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="3.13"/>
                    <measurement group_id="O2" value="1.4" spread="3.41"/>
                    <measurement group_id="O3" value="2.6" spread="6.80"/>
                    <measurement group_id="O4" value="4.1" spread="9.80"/>
                    <measurement group_id="O5" value="-0.5" spread="5.88"/>
                    <measurement group_id="O6" value="1.4" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Disability Assessment in Dementia (DAD) Score at Weeks 13, 26 and 39</title>
        <description>The DAD is a functional assessment based on an interview with the caregiver that takes approximately 20 min to administer and it is comprised of 40 items, 17 related to self-care and 23 items involving instrumental activities of daily living. The DAD is scored from 0 to 100 (higher scores indicate better functioning).</description>
        <time_frame>Baseline, Weeks 13, 26 and 39</time_frame>
        <population>All participants who were randomized to a treatment and received at least one infusion of study medication. n = number of evaluable participants at the corresponding timeframe.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disability Assessment in Dementia (DAD) Score at Weeks 13, 26 and 39</title>
          <description>The DAD is a functional assessment based on an interview with the caregiver that takes approximately 20 min to administer and it is comprised of 40 items, 17 related to self-care and 23 items involving instrumental activities of daily living. The DAD is scored from 0 to 100 (higher scores indicate better functioning).</description>
          <population>All participants who were randomized to a treatment and received at least one infusion of study medication. n = number of evaluable participants at the corresponding timeframe.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=6,6,16,17,24,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.5" spread="11.27"/>
                    <measurement group_id="O2" value="63.7" spread="31.89"/>
                    <measurement group_id="O3" value="78.6" spread="20.84"/>
                    <measurement group_id="O4" value="77.9" spread="17.91"/>
                    <measurement group_id="O5" value="84.8" spread="15.31"/>
                    <measurement group_id="O6" value="84.9" spread="12.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=6,6,15,16,22,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="8.82"/>
                    <measurement group_id="O2" value="-1.2" spread="14.22"/>
                    <measurement group_id="O3" value="-3.8" spread="11.61"/>
                    <measurement group_id="O4" value="-5.1" spread="15.57"/>
                    <measurement group_id="O5" value="-6.3" spread="12.71"/>
                    <measurement group_id="O6" value="-3.0" spread="7.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=6,5,14,14,18,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="9.20"/>
                    <measurement group_id="O2" value="-0.8" spread="12.30"/>
                    <measurement group_id="O3" value="-3.8" spread="10.20"/>
                    <measurement group_id="O4" value="-10.4" spread="14.93"/>
                    <measurement group_id="O5" value="0.2" spread="14.32"/>
                    <measurement group_id="O6" value="-2.5" spread="7.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 39 (n=6,4,14,14,19,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="8.40"/>
                    <measurement group_id="O2" value="0.5" spread="12.92"/>
                    <measurement group_id="O3" value="-6.9" spread="11.33"/>
                    <measurement group_id="O4" value="-14.6" spread="19.52"/>
                    <measurement group_id="O5" value="-1.9" spread="12.39"/>
                    <measurement group_id="O6" value="-1.8" spread="11.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Behavioral Symtoms as Measured by the Neuropsychiatric Inventory (NPI) at Weeks 13, 26 and 39</title>
        <description>The NPI is an instrument used to assess changes of behavior that have appeared in a defined period of time in participants with Alzheimer's disease (AD) and other dementias. Twelve (12) behavioral areas are assessed in the NPI  delusions, apathy, hallucinations, disinhibition, agitation, irritability, depression, aberrant motor behavior, anxiety, nighttime behaviors, euphoria, appetite, and eating changes. The NPI score is based on frequency and severity of specific behaviors within these categories as reported by the caregiver. A separate caregiver distress score may also be included. The NPI ranges from 0 to 144 (higher scores indicate greater psychopathology).</description>
        <time_frame>Baseline, Weeks 13, 26 and 39</time_frame>
        <population>All participants who were randomized to a treatment and received at least one infusion of study medication. n = number of evaluable participants at the corresponding timeframe.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Behavioral Symtoms as Measured by the Neuropsychiatric Inventory (NPI) at Weeks 13, 26 and 39</title>
          <description>The NPI is an instrument used to assess changes of behavior that have appeared in a defined period of time in participants with Alzheimer's disease (AD) and other dementias. Twelve (12) behavioral areas are assessed in the NPI  delusions, apathy, hallucinations, disinhibition, agitation, irritability, depression, aberrant motor behavior, anxiety, nighttime behaviors, euphoria, appetite, and eating changes. The NPI score is based on frequency and severity of specific behaviors within these categories as reported by the caregiver. A separate caregiver distress score may also be included. The NPI ranges from 0 to 144 (higher scores indicate greater psychopathology).</description>
          <population>All participants who were randomized to a treatment and received at least one infusion of study medication. n = number of evaluable participants at the corresponding timeframe.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=6,6,16,17,23,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="9.67"/>
                    <measurement group_id="O2" value="6.3" spread="9.18"/>
                    <measurement group_id="O3" value="9.1" spread="8.69"/>
                    <measurement group_id="O4" value="10.8" spread="11.46"/>
                    <measurement group_id="O5" value="7.7" spread="7.30"/>
                    <measurement group_id="O6" value="13.8" spread="12.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=6,6,15,15,21,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="4.80"/>
                    <measurement group_id="O2" value="4.8" spread="6.68"/>
                    <measurement group_id="O3" value="-0.7" spread="4.27"/>
                    <measurement group_id="O4" value="0.4" spread="7.31"/>
                    <measurement group_id="O5" value="0.3" spread="4.94"/>
                    <measurement group_id="O6" value="-2.1" spread="6.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=6,5,14,14,18,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="5.24"/>
                    <measurement group_id="O2" value="4.8" spread="4.09"/>
                    <measurement group_id="O3" value="-1.2" spread="2.94"/>
                    <measurement group_id="O4" value="4.6" spread="12.17"/>
                    <measurement group_id="O5" value="0.3" spread="6.01"/>
                    <measurement group_id="O6" value="-3.4" spread="8.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 39 (n=6,3,14,13,19,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="5.21"/>
                    <measurement group_id="O2" value="3.3" spread="2.52"/>
                    <measurement group_id="O3" value="0.6" spread="6.61"/>
                    <measurement group_id="O4" value="4.8" spread="17.07"/>
                    <measurement group_id="O5" value="0.1" spread="6.70"/>
                    <measurement group_id="O6" value="-2.6" spread="10.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline on the Clinical Dementia Rating (CDR) Sum of Boxes (CDR-SB) and Global CDR Rating at Weeks 26 and 39</title>
        <description>The CDR scale is a clinician-rated dementia staging instrument that tracks the progression of cognitive impairment in the following 6 categories  memory, orientation, judgment and problem solving, involvement in community affairs, home and hobbies, and personal care based on the CDR interview. The CDR is based on discussions between the clinician with the participant and caregiver using a structured format. A global CDR score is established by clinical scoring rules with values of 0 (no dementia), 0.5 (questionable dementia), 1 (mild dementia), 2 (moderate dementia), and 3 (severe dementia). A more quantitative version of the CDR scale is obtained by summing up the ratings in each of the 6 categories to provide the (CDR-SB). The CDR-SB scale ranges from 0 to 18 where higher score indicates severe dementia.</description>
        <time_frame>Baseline, Weeks 26 and 39</time_frame>
        <population>All participants who were randomized to a treatment and received at least one infusion of study medication. n = number of evaluable participants at the corresponding timeframe.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on the Clinical Dementia Rating (CDR) Sum of Boxes (CDR-SB) and Global CDR Rating at Weeks 26 and 39</title>
          <description>The CDR scale is a clinician-rated dementia staging instrument that tracks the progression of cognitive impairment in the following 6 categories  memory, orientation, judgment and problem solving, involvement in community affairs, home and hobbies, and personal care based on the CDR interview. The CDR is based on discussions between the clinician with the participant and caregiver using a structured format. A global CDR score is established by clinical scoring rules with values of 0 (no dementia), 0.5 (questionable dementia), 1 (mild dementia), 2 (moderate dementia), and 3 (severe dementia). A more quantitative version of the CDR scale is obtained by summing up the ratings in each of the 6 categories to provide the (CDR-SB). The CDR-SB scale ranges from 0 to 18 where higher score indicates severe dementia.</description>
          <population>All participants who were randomized to a treatment and received at least one infusion of study medication. n = number of evaluable participants at the corresponding timeframe.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CDS-SB - Baseline (n=6,6,16,17,24,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="1.673"/>
                    <measurement group_id="O2" value="11.17" spread="4.070"/>
                    <measurement group_id="O3" value="9.50" spread="4.351"/>
                    <measurement group_id="O4" value="10.94" spread="3.614"/>
                    <measurement group_id="O5" value="8.75" spread="3.566"/>
                    <measurement group_id="O6" value="8.89" spread="3.381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global CDR - Baseline (n=6,6,16,17,24,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.258"/>
                    <measurement group_id="O2" value="1.08" spread="0.492"/>
                    <measurement group_id="O3" value="1.03" spread="0.618"/>
                    <measurement group_id="O4" value="1.09" spread="0.476"/>
                    <measurement group_id="O5" value="0.85" spread="0.429"/>
                    <measurement group_id="O6" value="0.87" spread="0.467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDR-SB - Week 26 (n=6,5,14,14,18,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="1.751"/>
                    <measurement group_id="O2" value="1.40" spread="1.517"/>
                    <measurement group_id="O3" value="-0.07" spread="2.056"/>
                    <measurement group_id="O4" value="1.29" spread="2.758"/>
                    <measurement group_id="O5" value="0.17" spread="1.855"/>
                    <measurement group_id="O6" value="0.16" spread="1.979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global CDR - Week 26 (n=6,5,14,14,18,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.408"/>
                    <measurement group_id="O2" value="0.30" spread="0.447"/>
                    <measurement group_id="O3" value="0.04" spread="0.414"/>
                    <measurement group_id="O4" value="0.25" spread="0.510"/>
                    <measurement group_id="O5" value="0.03" spread="0.320"/>
                    <measurement group_id="O6" value="-0.03" spread="0.262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDR-SB - Week 39 (n=6,4,14,14,19,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="3.286"/>
                    <measurement group_id="O2" value="1.75" spread="1.708"/>
                    <measurement group_id="O3" value="1.00" spread="2.449"/>
                    <measurement group_id="O4" value="1.86" spread="3.371"/>
                    <measurement group_id="O5" value="0.79" spread="2.840"/>
                    <measurement group_id="O6" value="-0.35" spread="1.935"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global CDR - Week 39 (n=6,4,14,14,19,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.408"/>
                    <measurement group_id="O2" value="0.13" spread="0.250"/>
                    <measurement group_id="O3" value="0.04" spread="0.414"/>
                    <measurement group_id="O4" value="0.50" spread="0.679"/>
                    <measurement group_id="O5" value="0.13" spread="0.436"/>
                    <measurement group_id="O6" value="-0.06" spread="0.300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline on the Mini Mental State Exam (MMSE) Score at Weeks 13, 26, and 39</title>
        <description>The MMSE is a brief 30-point questionnaire test that is used to assess cognition. It is commonly used to screen for dementia. In the time span of about 10 min, it samples various functions, including arithmetic, memory and orientation. Scores range from 0 to 30 (higher scores indicate less impairment) and participants with scores of 16 to 26 were eligible.</description>
        <time_frame>Baseline, Weeks 13, 26 and 39</time_frame>
        <population>All participants who were randomized to a treatment and received at least one infusion of study medication. n = number of evaluable participants at the corresponding timeframe.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on the Mini Mental State Exam (MMSE) Score at Weeks 13, 26, and 39</title>
          <description>The MMSE is a brief 30-point questionnaire test that is used to assess cognition. It is commonly used to screen for dementia. In the time span of about 10 min, it samples various functions, including arithmetic, memory and orientation. Scores range from 0 to 30 (higher scores indicate less impairment) and participants with scores of 16 to 26 were eligible.</description>
          <population>All participants who were randomized to a treatment and received at least one infusion of study medication. n = number of evaluable participants at the corresponding timeframe.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=6,6,16,17,24,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" spread="1.37"/>
                    <measurement group_id="O2" value="22.5" spread="2.43"/>
                    <measurement group_id="O3" value="20.8" spread="3.71"/>
                    <measurement group_id="O4" value="20.1" spread="3.00"/>
                    <measurement group_id="O5" value="21.2" spread="2.82"/>
                    <measurement group_id="O6" value="21.2" spread="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=6,6,15,16,22,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="2.32"/>
                    <measurement group_id="O2" value="-0.5" spread="2.35"/>
                    <measurement group_id="O3" value="0.1" spread="2.45"/>
                    <measurement group_id="O4" value="-1.4" spread="2.78"/>
                    <measurement group_id="O5" value="0.9" spread="2.00"/>
                    <measurement group_id="O6" value="1.0" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=6,5,14,14,18,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.72"/>
                    <measurement group_id="O2" value="0.2" spread="1.10"/>
                    <measurement group_id="O3" value="0.0" spread="3.51"/>
                    <measurement group_id="O4" value="-2.0" spread="2.96"/>
                    <measurement group_id="O5" value="1.6" spread="2.91"/>
                    <measurement group_id="O6" value="0.7" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 39 (n=6,4,14,14,19,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="4.18"/>
                    <measurement group_id="O2" value="-1.0" spread="0.82"/>
                    <measurement group_id="O3" value="-0.2" spread="2.58"/>
                    <measurement group_id="O4" value="-2.2" spread="4.56"/>
                    <measurement group_id="O5" value="1.4" spread="3.55"/>
                    <measurement group_id="O6" value="0.5" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cerebrospinal Fluid (CSF) Concentration of AAB-003 at Week 32</title>
        <description>Participants enrolled in the 2, 4 and 8 mg/kg cohorts participated in an optional CSF collection. Participants enrolled in the maximum tolerated dose (MTD) cohort were mandatorily collected for CSF.</description>
        <time_frame>Week 32 or Early Withdrawal</time_frame>
        <population>All randomized and treated participants in the 2, 4 and 8 mg/kg cohorts who consented to the collection of CSF samples.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebrospinal Fluid (CSF) Concentration of AAB-003 at Week 32</title>
          <description>Participants enrolled in the 2, 4 and 8 mg/kg cohorts participated in an optional CSF collection. Participants enrolled in the maximum tolerated dose (MTD) cohort were mandatorily collected for CSF.</description>
          <population>All randomized and treated participants in the 2, 4 and 8 mg/kg cohorts who consented to the collection of CSF samples.</population>
          <units>nanogram/millliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.220">Standard deviation was not estimable since only one participant was evaluable</measurement>
                    <measurement group_id="O2" value="45.020">Standard deviation was not estimable since only one participant was evaluable</measurement>
                    <measurement group_id="O3" value="79.160" spread="53.0486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in CSF Amyloid-beta x-40 Concentration at Week 32 for AAB-003 8 mg/kg and Placebo Groups</title>
        <time_frame>Baseline and Week 32</time_frame>
        <population>The CSF analysis set consisted of participants in the AAB-003 8 mg/kg cohort who had provided sufficient CSF samples at Baseline and Week 32 to allow for assaying of both samples, and who had no occurrence of VE.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CSF Amyloid-beta x-40 Concentration at Week 32 for AAB-003 8 mg/kg and Placebo Groups</title>
          <population>The CSF analysis set consisted of participants in the AAB-003 8 mg/kg cohort who had provided sufficient CSF samples at Baseline and Week 32 to allow for assaying of both samples, and who had no occurrence of VE.</population>
          <units>picogram/milliliter (pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.53" spread="817.270"/>
                    <measurement group_id="O2" value="348.64" spread="1321.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change from baseline, within group</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.599</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean change</param_type>
            <param_value>113.53</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-170.30</ci_lower_limit>
            <ci_upper_limit>397.35</ci_upper_limit>
            <estimate_desc>One sample paired t-test</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>CSF Amyloid-beta x-40 Concentration at Baseline and Week 32 for AAB-003 2 mg/kg and 4 mg/kg Groups</title>
        <time_frame>Baseline and Week 32</time_frame>
        <population>The CSF analysis set consisted of participants in the AAB-003 8 mg/kg cohort who had provided sufficient CSF samples at Baseline and Week 32 to allow for assaying of both samples, and who had no occurrence of VE.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>CSF Amyloid-beta x-40 Concentration at Baseline and Week 32 for AAB-003 2 mg/kg and 4 mg/kg Groups</title>
          <population>The CSF analysis set consisted of participants in the AAB-003 8 mg/kg cohort who had provided sufficient CSF samples at Baseline and Week 32 to allow for assaying of both samples, and who had no occurrence of VE.</population>
          <units>picogram/milliliter (pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5685.4">There were insufficient numbers of participants for group analysis.</measurement>
                    <measurement group_id="O2" value="7413.6">There were insufficient numbers of participants for group analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5836.1">There were insufficient numbers of participants for group analysis.</measurement>
                    <measurement group_id="O2" value="8883.2">There were insufficient numbers of participants for group analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in CSF Amyloid-beta x-42 Concentration at Week 32 for AAB-003 8 mg/kg and Placebo Groups</title>
        <time_frame>Baseline and Week 32</time_frame>
        <population>The CSF analysis set consisted of participants in the AAB-003 8 mg/kg cohort who had provided sufficient CSF samples at Baseline and Week 32 to allow for assaying of both samples, and who had no occurrence of VE.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CSF Amyloid-beta x-42 Concentration at Week 32 for AAB-003 8 mg/kg and Placebo Groups</title>
          <population>The CSF analysis set consisted of participants in the AAB-003 8 mg/kg cohort who had provided sufficient CSF samples at Baseline and Week 32 to allow for assaying of both samples, and who had no occurrence of VE.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.85" spread="174.589"/>
                    <measurement group_id="O2" value="24.04" spread="173.610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change from baseline, within group</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.297</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean change</param_type>
            <param_value>48.85</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.79</ci_lower_limit>
            <ci_upper_limit>109.48</ci_upper_limit>
            <estimate_desc>One sample paired t-test</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>CSF Amyloid-beta x-42 Concentration at Baseline and Week 32 for AAB-003 2 mg/kg and 4 mg/kg Groups</title>
        <time_frame>Baseline and Week 32</time_frame>
        <population>The CSF analysis set consisted of participants in the AAB-003 8 mg/kg cohort who had provided sufficient CSF samples at Baseline and Week 32 to allow for assaying of both samples, and who had no occurrence of VE.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>CSF Amyloid-beta x-42 Concentration at Baseline and Week 32 for AAB-003 2 mg/kg and 4 mg/kg Groups</title>
          <population>The CSF analysis set consisted of participants in the AAB-003 8 mg/kg cohort who had provided sufficient CSF samples at Baseline and Week 32 to allow for assaying of both samples, and who had no occurrence of VE.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="485.6">There were insufficient numbers of participants for group analysis.</measurement>
                    <measurement group_id="O2" value="217.2">There were insufficient numbers of participants for group analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="343.3">There were insufficient numbers of participants for group analysis.</measurement>
                    <measurement group_id="O2" value="331">There were insufficient numbers of participants for group analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in CSF Tau Concentration at Week 32 for AAB-003 8 mg/kg and Placebo Groups</title>
        <time_frame>Baseline and Week 32</time_frame>
        <population>The CSF analysis set consisted of participants in the AAB-003 8 mg/kg cohort who had provided sufficient CSF samples at Baseline and Week 32 to allow for assaying of both samples, and who had no occurrence of VE.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CSF Tau Concentration at Week 32 for AAB-003 8 mg/kg and Placebo Groups</title>
          <population>The CSF analysis set consisted of participants in the AAB-003 8 mg/kg cohort who had provided sufficient CSF samples at Baseline and Week 32 to allow for assaying of both samples, and who had no occurrence of VE.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.26" spread="110.229"/>
                    <measurement group_id="O2" value="67.94" spread="63.514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change from baseline, within group</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.600</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean change</param_type>
            <param_value>-15.26</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.54</ci_lower_limit>
            <ci_upper_limit>23.02</ci_upper_limit>
            <estimate_desc>One sample paired t-test</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>CSF Tau Concentration at Baseline and Week 32 for AAB-003 2 mg/kg and 4 mg/kg Groups</title>
        <time_frame>Baseline and Week 32</time_frame>
        <population>The CSF analysis set consisted of participants in the AAB-003 8 mg/kg cohort who had provided sufficient CSF samples at Baseline and Week 32 to allow for assaying of both samples, and who had no occurrence of VE.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>CSF Tau Concentration at Baseline and Week 32 for AAB-003 2 mg/kg and 4 mg/kg Groups</title>
          <population>The CSF analysis set consisted of participants in the AAB-003 8 mg/kg cohort who had provided sufficient CSF samples at Baseline and Week 32 to allow for assaying of both samples, and who had no occurrence of VE.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="659.6">There were insufficient numbers of participants for group analysis.</measurement>
                    <measurement group_id="O2" value="856.1">There were insufficient numbers of participants for group analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="739.4">There were insufficient numbers of participants for group analysis.</measurement>
                    <measurement group_id="O2" value="1115.6">There were insufficient numbers of participants for group analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in CSF P-tau Concentration at Week 32 for AAB-003 8 mg/kg and Placebo Groups</title>
        <time_frame>Baseline and Week 32</time_frame>
        <population>The CSF analysis set consisted of participants in the AAB-003 8 mg/kg cohort who had provided sufficient CSF samples at Baseline and Week 32 to allow for assaying of both samples, and who had no occurrence of VE.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CSF P-tau Concentration at Week 32 for AAB-003 8 mg/kg and Placebo Groups</title>
          <population>The CSF analysis set consisted of participants in the AAB-003 8 mg/kg cohort who had provided sufficient CSF samples at Baseline and Week 32 to allow for assaying of both samples, and who had no occurrence of VE.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="8.986"/>
                    <measurement group_id="O2" value="1.92" spread="7.755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change from baseline, within group</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.603</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean change</param_type>
            <param_value>1.23</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.89</ci_lower_limit>
            <ci_upper_limit>4.35</ci_upper_limit>
            <estimate_desc>One sample paired t-test</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>CSF P-tau Concentration at Baseline and Week 32 for AAB-003 2 mg/kg and 4 mg/kg Groups</title>
        <time_frame>Baseline and Week 32</time_frame>
        <population>The CSF analysis set consisted of participants in the AAB-003 8 mg/kg cohort who had provided sufficient CSF samples at Baseline and Week 32 to allow for assaying of both samples, and who had no occurrence of VE.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>CSF P-tau Concentration at Baseline and Week 32 for AAB-003 2 mg/kg and 4 mg/kg Groups</title>
          <population>The CSF analysis set consisted of participants in the AAB-003 8 mg/kg cohort who had provided sufficient CSF samples at Baseline and Week 32 to allow for assaying of both samples, and who had no occurrence of VE.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89">There were insufficient numbers of participants for group analysis.</measurement>
                    <measurement group_id="O2" value="122.7">There were insufficient numbers of participants for group analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.3">There were insufficient numbers of participants for group analysis.</measurement>
                    <measurement group_id="O2" value="140.5">There were insufficient numbers of participants for group analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maximum Observed Plasma Concentration (Cmax) for Amyloid-Beta x-40</title>
        <time_frame>Weeks 1, 3, 6, 10, 13 (pre-dose, 1 hour [end of infusion]), Week 26 (pre-dose, 1 hour [end of infusion], 1.5, 2, 4, 6, and 24 hours post start of infusion), and Weeks 32 and 39.</time_frame>
        <population>All randomized participants who received at least one infusion of study medication and have at least one postdose pharmacodynamic (PD) parameter assessment. n = number of evaluable participants at the corresponding timeframe.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) for Amyloid-Beta x-40</title>
          <population>All randomized participants who received at least one infusion of study medication and have at least one postdose pharmacodynamic (PD) parameter assessment. n = number of evaluable participants at the corresponding timeframe.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 - Week 13 (n=6,5,14,16,22,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.321" spread="50"/>
                    <measurement group_id="O2" value="6.959" spread="29"/>
                    <measurement group_id="O3" value="8.202" spread="19"/>
                    <measurement group_id="O4" value="11.89" spread="10"/>
                    <measurement group_id="O5" value="18.03" spread="19"/>
                    <measurement group_id="O6" value="0.3511" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 - Week 39 (n=5,4,14,14,17,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.964" spread="35"/>
                    <measurement group_id="O2" value="3.805" spread="31"/>
                    <measurement group_id="O3" value="3.804" spread="23"/>
                    <measurement group_id="O4" value="7.537" spread="26"/>
                    <measurement group_id="O5" value="12.25" spread="20"/>
                    <measurement group_id="O6" value="0.4689" spread="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) for Amyloid-Beta x-40</title>
        <time_frame>Weeks 1, 3, 6, 10, 13 (pre-dose, 1 hour [end of infusion]), Week 26 (pre-dose, 1 hour [end of infusion], 1.5, 2, 4, 6, and 24 hours post start of infusion), and Weeks 32 and 39.</time_frame>
        <population>All randomized participants who received at least one infusion of study medication, had a Baseline PD parameter assessment and at least one post-dose PD parameter assessment. n = number of evaluable participants at the corresponding timeframe.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) for Amyloid-Beta x-40</title>
          <population>All randomized participants who received at least one infusion of study medication, had a Baseline PD parameter assessment and at least one post-dose PD parameter assessment. n = number of evaluable participants at the corresponding timeframe.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 - Week 13 (n=6,5,14,16,22,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2" spread="50" lower_limit="22.3" upper_limit="149"/>
                    <measurement group_id="O2" value="24.0" spread="29" lower_limit="24.0" upper_limit="169"/>
                    <measurement group_id="O3" value="24.0" spread="19" lower_limit="24.0" upper_limit="170"/>
                    <measurement group_id="O4" value="166" spread="10" lower_limit="24.0" upper_limit="238"/>
                    <measurement group_id="O5" value="164" spread="19" lower_limit="92.2" upper_limit="1050"/>
                    <measurement group_id="O6" value="168" spread="25" lower_limit="0.000" upper_limit="2540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 - Week 39 (n=5,4,14,14,17,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="35" lower_limit="2.02" upper_limit="596"/>
                    <measurement group_id="O2" value="2.00" spread="31" lower_limit="2.00" upper_limit="2.02"/>
                    <measurement group_id="O3" value="983" spread="23" lower_limit="2.00" upper_limit="1080"/>
                    <measurement group_id="O4" value="1010" spread="26" lower_limit="958" upper_limit="1060"/>
                    <measurement group_id="O5" value="1010" spread="20" lower_limit="1.98" upper_limit="1080"/>
                    <measurement group_id="O6" value="1030" spread="84" lower_limit="0.000" upper_limit="2210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Amyloid-Beta x-40</title>
        <time_frame>Baseline; Day 2 (24 hours post start of infusion); Weeks 1, 6, and 13 (pre-dose, 1 hour [end of infusion]), Week 26 (pre-dose, 1 hour [end of infusion], 1.5, 2, 4, 6, and 24 hours post start of infusion), and Weeks 32 and 39.</time_frame>
        <population>All randomized participants who received at least one infusion of study medication, had a Baseline PD parameter assessment, at least one post-dose PD parameter assessment, and who had available data for AUClast.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Amyloid-Beta x-40</title>
          <population>All randomized participants who received at least one infusion of study medication, had a Baseline PD parameter assessment, at least one post-dose PD parameter assessment, and who had available data for AUClast.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2664" spread="31" lower_limit="22.3" upper_limit="149"/>
                    <measurement group_id="O2" value="6041" spread="47" lower_limit="24.0" upper_limit="169"/>
                    <measurement group_id="O3" value="7836" spread="19" lower_limit="24.0" upper_limit="170"/>
                    <measurement group_id="O4" value="12970" spread="17" lower_limit="24.0" upper_limit="238"/>
                    <measurement group_id="O5" value="22910" spread="25" lower_limit="92.2" upper_limit="1050"/>
                    <measurement group_id="O6" value="639.7" spread="23" lower_limit="0.000" upper_limit="2540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for Amyloid-Beta x-40</title>
        <time_frame>Baseline; Day 2 (24 hours post start of infusion); Weeks 1, 6, and 13 (pre-dose, 1 hour [end of infusion]), Week 26 (pre-dose, 1 hour [end of infusion], 1.5, 2, 4, 6, and 24 hours post start of infusion), and Weeks 32 and 39.</time_frame>
        <population>All randomized participants who received at least one infusion of study medication, had a Baseline PD parameter assessment, at least one post-dose PD parameter assessment, and who had available data for AUCinf. No participants had available data for AUCinf in AAB-003 8 mg/kg and Placebo Groups.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for Amyloid-Beta x-40</title>
          <population>All randomized participants who received at least one infusion of study medication, had a Baseline PD parameter assessment, at least one post-dose PD parameter assessment, and who had available data for AUCinf. No participants had available data for AUCinf in AAB-003 8 mg/kg and Placebo Groups.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2916">Standard deviation was not estimable since only one participant was evaluable</measurement>
                    <measurement group_id="O2" value="5463">Standard deviation was not estimable since only one participant was evaluable</measurement>
                    <measurement group_id="O3" value="8965" spread="19"/>
                    <measurement group_id="O4" value="12800" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for Amyloid-Beta x-40</title>
        <time_frame>Weeks 1, 3, 6, 10, 13 (pre-dose, 1 hour [end of infusion]), Week 26 (pre-dose, 1 hour [end of infusion], 1.5, 2, 4, 6, and 24 hours post start of infusion), and Weeks 32 and 39.</time_frame>
        <population>All randomized participants who received at least one infusion of study medication, had a Baseline PD parameter assessment, and at least one post-dose PD parameter assessment. n = number of evaluable participants at the corresponding timeframe.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for Amyloid-Beta x-40</title>
          <population>All randomized participants who received at least one infusion of study medication, had a Baseline PD parameter assessment, and at least one post-dose PD parameter assessment. n = number of evaluable participants at the corresponding timeframe.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 - Week 13 (n=6,5,14,16,22,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2647" spread="31" lower_limit="22.3" upper_limit="149"/>
                    <measurement group_id="O2" value="6057" spread="47" lower_limit="24.0" upper_limit="169"/>
                    <measurement group_id="O3" value="7854" spread="19" lower_limit="24.0" upper_limit="170"/>
                    <measurement group_id="O4" value="12940" spread="17" lower_limit="24.0" upper_limit="238"/>
                    <measurement group_id="O5" value="22820" spread="26" lower_limit="92.2" upper_limit="1050"/>
                    <measurement group_id="O6" value="631.6" spread="23" lower_limit="0.000" upper_limit="2540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 - Week 39 (n=5,4,14,14,17,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2614" spread="32" lower_limit="2.02" upper_limit="596"/>
                    <measurement group_id="O2" value="4929" spread="37" lower_limit="2.00" upper_limit="2.02"/>
                    <measurement group_id="O3" value="6119" spread="31" lower_limit="2.00" upper_limit="1080"/>
                    <measurement group_id="O4" value="11910" spread="26" lower_limit="958" upper_limit="1060"/>
                    <measurement group_id="O5" value="19740" spread="25" lower_limit="1.98" upper_limit="1080"/>
                    <measurement group_id="O6" value="798.8" spread="55" lower_limit="0.000" upper_limit="2210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Plasma Decay Half-Life (t1/2) for Amyloid-Beta x-40</title>
        <time_frame>Baseline; Day 2 (24 hours post start of infusion); Weeks 1, 6, and 13 (pre-dose, 1 hour [end of infusion]), Week 26 (pre-dose, 1 hour [end of infusion], 1.5, 2, 4, 6, and 24 hours post start of infusion), and Weeks 32 and 39.</time_frame>
        <population>All randomized participants who received at least one infusion of study medication, had a Baseline PD parameter assessment, at least one post-dose PD parameter assessment, and who had available data for t1/2. No participants had available data for t1/2 in AAB-003 8 mg/kg and Placebo Groups.</population>
        <group_list>
          <group group_id="O1">
            <title>AAB-003 0.5 mg/kg</title>
            <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O2">
            <title>AAB-003 1 mg/kg</title>
            <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O3">
            <title>AAB-003 2 mg/kg</title>
            <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O4">
            <title>AAB-003 4 mg/kg</title>
            <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O5">
            <title>AAB-003 8 mg/kg</title>
            <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Decay Half-Life (t1/2) for Amyloid-Beta x-40</title>
          <population>All randomized participants who received at least one infusion of study medication, had a Baseline PD parameter assessment, at least one post-dose PD parameter assessment, and who had available data for t1/2. No participants had available data for t1/2 in AAB-003 8 mg/kg and Placebo Groups.</population>
          <units>Day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.57">Standard deviation was not estimable since only one participant was evaluable</measurement>
                    <measurement group_id="O2" value="32.14">Standard deviation was not estimable since only one participant was evaluable</measurement>
                    <measurement group_id="O3" value="30.71" spread="3.2303"/>
                    <measurement group_id="O4" value="29.41" spread="5.7374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to 39 weeks</time_frame>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>AAB-003 0.5 mg/kg</title>
          <description>Participants received AAB-003 0.5 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
        </group>
        <group group_id="E2">
          <title>AAB-003 1 mg/kg</title>
          <description>Participants received AAB-003 1 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
        </group>
        <group group_id="E3">
          <title>AAB-003 2 mg/kg</title>
          <description>Participants received AAB-003 2 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
        </group>
        <group group_id="E4">
          <title>AAB-003 4 mg/kg</title>
          <description>Participants received AAB-003 4 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
        </group>
        <group group_id="E5">
          <title>AAB-003 8 mg/kg</title>
          <description>Participants received AAB-003 8 mg/kg by IV infusion on Day 1, Week 13 and Week 26</description>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
          <description>Participants received placebo matched to AAB-003 by IV infusion on Day 1, Week 13 and Week 26</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Microhaemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vasogenic Cerebral Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Disorder</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Deafness Unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival Hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Tooth Impacted</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gingival Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion Site Bruising</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gait Disturbance</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infusion Site Erythema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infusion Site Haemorrhage</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infusion Site Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infusion Site Swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Tooth Infection</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Post Lumbar Puncture Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymph Node Palpable</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Otoscopy Abnormal</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood Bilirubin Abnormal</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Weight Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Glucose Tolerance Impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Joint Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Mesenteric Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sinus Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Bradykinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lacunar Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Coordination Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Depressed Mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sleep Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Insomina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypersexuality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Incontinence</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Calculus Ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Renal Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rhinitis Allergic</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dermatitis Contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flush</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Aortic Calcification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

